Last reviewed · How we verify
NK cell infusions
At a glance
| Generic name | NK cell infusions |
|---|---|
| Sponsor | Belarusian Research Center for Pediatric Oncology, Hematology and Immunology |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
- Febrile neutropenia
- Febrile Neutropenia
- Hypokalemia
- Anemia
- Lymphocyte count decreased
- Neutrophil count decreased
- Platelet count decreased
- White blood cell decreased
- Hypophosphatemia
- Mucositis oral
- Hyperglycemia
- Nausea
Key clinical trials
- Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID) (PHASE1, PHASE2)
- Phase1 Basket Trial Of CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed/Refractory Lymphoid Malignancies (PHASE1)
- Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial Carcinoma (PHASE1)
- Nogapendekin Alfa-Inbakicept and iNKT Cells for Critically Ill Adults With Severe Community-Acquired Pneumonia (With or Without Sepsis/ARDS) (PHASE2)
- NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial (PHASE2)
- Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells (PHASE1)
- Natural Killer Cells and Bortezomib to Treat Cancer (PHASE1)
- Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: